The addition of immunotherapy to standard first-line treatment extends survival by eight months for patients with recurrent, persistent or metastatic cervical cancer, according to late breaking results from the KEYNOTE-826 ...
Sep 20, 2021
0
15
Younger patients with resected melanoma had some benefit from adjuvant treatment with the anti-VEGF therapeutic bevacizumab (Avastin) while older patients with resected melanoma did not, according to results published in ...
Oct 23, 2020
0
0
(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovarian cancer, according ...
Dec 19, 2019
0
0
Combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab significantly improves overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC) ...
Nov 22, 2019
0
6
New data presented at the ESMO Congress 2019 in Barcelona, Spain, show the benefit of a more intensive maintenance regimen for ovarian cancer with the PARP inhibitor olaparib added to bevacizumab, in an all-comers population, ...
Sep 28, 2019
0
5
(HealthDay)—The addition of bevacizumab to carboplatin/pemetrexed is associated with improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to a study published in the May issue ...
Jun 18, 2019
0
1
Glioblastoma is the most common kind of brain tumour in adults. It is a very aggressive form of cancer; patients with this diagnosis have a median post-diagnosis survival of 15 months. Especially in the US, the drug Bevacizumab ...
Apr 2, 2019
0
4
A treatment combination has been provisionally rejected for people with certain types of lung cancer on the NHS in England.
Feb 12, 2019
0
0
A team of researchers from the UCH CEU's Biomedical Sciences Institute has tested the efficiency of Bevacizumab, medicine used against cancer and in opthalmology, to treat uveítis, thus stopping the inflammation from spreading.
Oct 22, 2018
0
1
(HealthDay)—For patients with metastatic renal cell carcinoma (mRCC), atezolizumab plus bevacizumab is associated with a progression-free survival benefit versus sunitinib, according to a study presented at the American ...
Feb 9, 2018
0
1
